News
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports US Collab. Partner announces Submission to FDA seeking EUA for Aviptadil for Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-Adhoc: Orell Füssli AG: Orell Füssli and Swisscom enter into strategic partnership for digital certificates
EQS-Adhoc: Orell Füssli AG: Orell Füssli and Swisscom enter into strategic partnership for digital certificates
EQS-Adhoc: Orell Füssli AG: Orell Füssli und Swisscom schliessen strategische Partnerschaft für digitale Nachweise
EQS-Adhoc: Orell Füssli AG: Orell Füssli und Swisscom schliessen strategische Partnerschaft für digitale Nachweise
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Jungfraubahn Holding AG: Jungfraubahn-Gruppe - Gästezahlen weiterhin von der Pandemie beeinflusst
EQS-Adhoc: Jungfraubahn Holding AG: Jungfraubahn-Gruppe - Gästezahlen weiterhin von der Pandemie beeinflusst
EQS-Adhoc: Jungfraubahn Holding AG: Jungfrau Railway Group - Guest numbers continue to be affected by the pandemic
EQS-Adhoc: Jungfraubahn Holding AG: Jungfrau Railway Group - Guest numbers continue to be affected by the pandemic
EQS-Adhoc: HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021
EQS-Adhoc: HBM Healthcare Investments delivers strong return despite weak biotech sector and increases net asset value per share (NAV) by 19 percent in calendar year 2021
EQS-Adhoc: HBM Healthcare Investments liefert trotz schwachem Biotechsektor starke Performance und steigert im Kalenderjahr 2021 den inneren Wert je Aktie (NAV) um 19 Prozent
EQS-Adhoc: HBM Healthcare Investments liefert trotz schwachem Biotechsektor starke Performance und steigert im Kalenderjahr 2021 den inneren Wert je Aktie (NAV) um 19 Prozent
EQS-Adhoc: Burkhalter Gruppe vollzieht Kauf der Elektrohüs AG
EQS-Adhoc: Burkhalter Gruppe vollzieht Kauf der Elektrohüs AG
EQS-Adhoc: Burkhalter Group completes acquisition of Elektrohüs AG
EQS-Adhoc: Burkhalter Group completes acquisition of Elektrohüs AG
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Burkhalter Gruppe vollzieht Änderungen in der Gruppengeschäftsleitung
EQS-Adhoc: Burkhalter Gruppe vollzieht Änderungen in der Gruppengeschäftsleitung
EQS-Adhoc: Burkhalter Group is making changes to the Group Management Board
EQS-Adhoc: Burkhalter Group is making changes to the Group Management Board
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-News: Meyer Burger to bring 400 MW high-performance solar module manufacturing facility and hundreds of jobs to Arizona, plans to scale site to 1.5 GW capacity
EQS-News: Meyer Burger to bring 400 MW high-performance solar module manufacturing facility and hundreds of jobs to Arizona, plans to scale site to 1.5 GW capacity
EQS-News: Meyer Burger baut 400 Megawatt Hochleistungs-Solarmodulproduktion in Arizona auf, schafft Hunderte von Arbeitsplätzen und plant die Erweiterung auf 1,5 Gigawatt Kapazität
EQS-News: Meyer Burger baut 400 Megawatt Hochleistungs-Solarmodulproduktion in Arizona auf, schafft Hunderte von Arbeitsplätzen und plant die Erweiterung auf 1,5 Gigawatt Kapazität
EQS-Adhoc: CALIDA GROUP receives binding offer for sale of MILLET MOUNTAIN GROUP
EQS-Adhoc: CALIDA GROUP receives binding offer for sale of MILLET MOUNTAIN GROUP
EQS-Adhoc: CALIDA GROUP erhält verbindliches Angebot für Verkauf der MILLET MOUNTAIN GROUP
EQS-Adhoc: CALIDA GROUP erhält verbindliches Angebot für Verkauf der MILLET MOUNTAIN GROUP
EQS-Adhoc: Leclanché gibt ein Update zur Geschäftsentwicklung bekannt
EQS-Adhoc: Leclanché gibt ein Update zur Geschäftsentwicklung bekannt